Assessing the Antifungal Activity of a New Oral Lipid-Based Amphotericin B Formulation Following Administration to Rats Infected with Aspergillus Fumigatus

By Risovic Verica   Rosland Mike   Sivak Olena   Wasan Kishor M.   Bartlett Karen  

Drug Development and Industrial Pharmacy, Vol. 33, Iss. 7, 2007-07 ,pp. : 703-707

Informa Healthcare

Access to resources Recommend Favorite

Toxicity of amphotericin B to analbuminemic rats

By Marzzullo L.   Oliveira E.P.   Souza L.C.   Campa A.  

Environmental Toxicology and Pharmacology, Vol. 2, Iss. 1, 1996-08 ,pp. : 31-34

Elsevier

Access to resources Recommend Favorite

Pharmacokinetics and Renal Toxicity of Monomeric Amphotericin B in Rats after a Multiple Dose Regimen

By  

Pharmaceutical Nanotechnology, Vol. 4, Iss. 1, 2016-04 ,pp. : 16-23

Bentham Science Publishers

Access to resources Recommend Favorite

Amphotericin B-Gum Arabic Conjugates: Synthesis, Toxicity, Bioavailability, and Activities Against Leishmania and Fungi

By Nishi K.   Antony M.   Mohanan P.   Anilkumar T.   Loiseau P.   Jayakrishnan A.  

Pharmaceutical Research, Vol. 24, Iss. 5, 2007-05 ,pp. : 971-980

Springer Publishing Company

Access to resources Recommend Favorite

Differences in human phospholipid transfer protein activity following incubation of Fungizone® compared to lipid-based Amphotericin-B formulations in normolipidemic and hyperlipidemic plasma

By Henderson Ryan J.   Leon Carlos G.   Wasan Kishor M.  

Drug Development and Industrial Pharmacy, Vol. 35, Iss. 9, 2009-09 ,pp. : 1139-1146

Informa Healthcare

Access to resources Recommend Favorite